Vivus (VVUS)

VVUS (NASDAQ:Drugs)
$3.41
pos +0.00
+0.00%
Today's Range: 3.34 - 3.49 | VVUS Avg Daily Volume: 2,187,300
Last Update: 10/24/14 - 4:00 PM EDT
Volume: 0
YTD Performance: -62.44%
Open: $0.00
Previous Close: $3.40
52 Week Range: $3.13 - $10.29
Oustanding Shares: 103,460,015
Market Cap: 351,764,051
6-Month Chart
TheStreet Ratings Grade for VVUS
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 0 1 1 1
Moderate Buy 0 0 0 0
Hold 2 2 3 4
Moderate Sell 2 2 2 2
Strong Sell 2 2 2 2
Mean Rec. 4.00 3.57 3.50 3.44
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -3.27
Price Earnings Comparisons:
VVUS Sector Avg. S&P 500
-3.27 0.00 28.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-30.41% -64.07% -61.94%
GROWTH 12 Mo 3 Yr CAGR
Revenue 3,929.90 0.00 0.00
Net Income 0.00 1.32 0.00
EPS 0.00 1.10 0.00
Earnings for VVUS:
EBITDA -0.11B
Revenue 0.08B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.21 $-0.28 $-1.06 $-1.25
Number of Analysts 4 3 6 6
High Estimate $-0.07 $-0.24 $-0.74 $-0.83
Low Estimate $-0.45 $-0.32 $-1.52 $-2.13
Prior Year $-0.48 $-0.12 $-1.51 $-1.06
Growth Rate (Year over Year) 55.73% -130.56% 29.91% -17.95%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Looking at What Didn't Work Real Money Pro($)

Time to examine a couple that didn't pan out.
Bearish
Oct 16, 2013 | 8:52 AM EDT
VVUS was downgraded to Neutral from Overweight, according to Piper Jaffray. Headwind from increased competition and lack of partnership...

2 Ways to Play Vivus Real Money Pro($)

The short-term picture has changed.

Viva La Vivus? Real Money Pro($)

This looks ready to make a move higher.
Some of the market's favorite stocks have entered a danger zone.
Bearish
Sep 04, 2013 | 7:33 AM EDT
VVUS was downgraded to Sell, Lazard Capital Markets said. $8 price target. Qsymia has had a slow launch and the company's patents could...
Bearish
Aug 07, 2013 | 7:44 AM EDT
VVUS estimates lowered through 2013, Jefferies said. $5 price target. Weak 2Q but signs of acceleration in 3Q. Underperform rating.&nbs...
Bearish
Jul 23, 2013 | 8:15 AM EDT
VVUS was removed from the US1 list, according to Bank of America/Merrill Lynch. An inflection in Qsymia prescriptions could take time. ...
Bearish
Jul 15, 2013 | 8:25 AM EDT
VVUS was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $15 price target. 
Liquidity is key, and one ETF stands above the rest.

Columnist Conversations

GS has cleared the important hurdle on the way up which increases the odds for an eventual rally towards the 1...
A good quarterly report has sent shares of Calamos Asset Management (CLMS) sharply higher. CLMS was up about ...
Electronics distributor Ingram Micro (IM) reported better than 16% growth in its Q3 sending the stock up about...
Market posting decent day considering Ebola getting headlines again. Believe investors have learned not to pa...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.